Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy, received clearance for Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) on March 12.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments